Rapid Medical’s Tigertriever 25 Cleared by FDA to Treat LVO Stroke

April 16, 2026—Rapid Medical announced FDA clearance of the Tigertriever 25 thrombectomy device. Additionally, the company announced that the first clinical cases with the device were performed to treat large vessel occlusion (LVO) stroke.

According to the company, the Tigertriever 25 is designed to address large clot burden in proximal vessels such as the internal carotid artery (ICA) and M1 segment. It combines a 53-mm capture length with the company’s real-time force control. This feature enables physicians to actively control clot interaction during procedures for consistent performance across a wide range of clinical scenarios, including long thrombi and stenotic vessels.

Additionally, the device combines extended capture length, active operator-controlled expansion, and a distal net designed to maintain clot engagement over long segments.

The first case with the device in the United States was performed by Edgar Samaniego, MD, of the University of Iowa in Iowa City, Iowa.

“With every thrombectomy, we aim at our first pass being the last,” commented Dr. Samaniego in Rapid Medical’s press release. “The Tigertriever 25 demonstrated excellent conformability to the vessel anatomy, accommodating the middle cerebral artery diameter with a smooth transition into the terminal ICA. This adaptability allows for effective engagement across long segments and makes it particularly valuable in LVOs with high clot burden, even in challenging, angulated anatomy.”

Demetrius Lopes, MD, of Advocate Health Care in Chicago, Illinois, added, “Acute ischemic stroke intervention today demands a diverse and adaptable toolkit to effectively address the wide spectrum of anatomical and clinical scenarios we encounter, and I am very impressed with the versatility of the Tigertriever 25 device.

“Its design streamlines the procedural approach and has the potential to simplify the pathway to achieving first-pass success—an outcome that remains critical for improving patient outcomes in mechanical thrombectomy.”